companies / augustinetherapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 108,000,000108.0M | ○ |
|---|---|---|
| founded | 2018 | |
| hq | Leuven | |
| industry | unknown | |
| stage | series-a |
Clinical-stage biotech developing selective HDAC6 inhibitors for neuromuscular, neurodegenerative and cardio-metabolic disease. Patients with Charcot-Marie-Tooth, ALS and related conditions are the initial focus. A novel non-hydroxamate, non-hydrazide chemotype preserves HDAC6's beneficial functions, making it suited to chronic dosing.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-06-01 | series-a | 91,800,00091.8M | null | ○ |
| fact | status | src |
|---|---|---|
| Series A, $91.8M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |